Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

New Cloud Platform “STB CLOUD” Disrupts AI Drug Discovery Worldwide (KOSDAQ:226330.KQ)

Syntekabio, Inc.

Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, has launched STB CLOUD worldwide. Running on Syntekabio’s own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology. It can process small molecule drug discovery on any device, anytime and anywhere. STB CLOUD outperforms common Software as a Service (SaaS) options in the market. By integrating DeepMatcher ®, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and database into the cloud system. Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources. It generates a comprehensive automatic report, including active substance candidates with users’ minimum input, for instance, only by inputting the name of the target protein related to a disease of interest. “We live in a rapidly changing world with constant disruptions by new and advanced technologies. STB CLOUD is an instant game changer for faster, easier and more accurate drug discovery. Investing in technologies like this further supports clinical trials critical for making lifesaving drugs in a timely manner,” said the CEO of Syntekabio, Jongsun Jung, Ph.D. “This landmark achievement will undoubtedly strengthen Syntekabio’s position in the competitive AI drug discovery industry. Bringing STB CLOUD to the global marketplace has been a tremendous endeavor by our exceptional scientists and engineers.” For the evaluation of automated drug discovery performance in STB CLOUD, DeepMatcher ® was used for 10 target proteins with a library of 120 million compounds available for quick purchase. The evaluation included compounds with known binding affinity as positive controls in the compound library and tracked the number of positive controls recovered during the DeepMatcher ® process, which is comprised of three steps: 3D screening, optimal pose and validation. After the first step, the average recovery rate was 31 percent among 1,000 top-ranked candidates. At the completion of the final validation step (MD simulation), the recovery rate resulted in an average of 16 percent among 200 final-ranked candidates for 10 targets. These outstanding results prove not only the power of STB CLOUD but the potential of DeepMatcher ® itself in the overall drug discovery industry. Syntekabio is already working on further strengthening STB CLOUD, with a neoantigen prediction platform (NEO-ARS™) and a multivariate biomarker prediction and discovery platform (PGM-ARS™), to be used for supporting clinical trials with a selection of patients in the near future. Additionally, the company’s new high-performance supercomputing center with 10,000 CPU/GPU computing servers is underway to be completed in the first half of 2023. For business development meetings and information about Syntekabio’s products and services, contact the New York office at +1 (212) 371-2544 or admin@syntekabiousa.com. More information about STB CLOUD is available at cloud.syntekabio.com. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng

December 16, 2022 11:00 AM Eastern Standard Time

FOR THIRD CONSECUTIVE YEAR HIBBETT AND PUMA PARTNER ON GENEROUS CHILDREN’S OF ALABAMA DONATION

Hibbett, Inc.

Hibbett, Inc., leading Birmingham-based premium footwear and athletic-inspired fashion retailer, today announced a donation to Children’s of Alabama in partnership with leading global sports brand company, PUMA. The donation of $20,000 and more than $30,000 worth of apparel, footwear and toys were presented to the hospital staff on Tuesday, December 13, 2022. For the third consecutive year, donations from Hibbett and PUMA will benefit the Care Closet in Social Services, Child Life's Sugar Plum Shop and the CHIPS Center, which all focus on providing family centered care for patients and their families. The Care Closet is utilized by social workers from every division at Children's on a daily basis, and shoes and clothing items are frequently needed, but not always readily available. On average, the team provides more than 400 families in crisis with essential items each year. The Care Closet donations allow those who arrive at the hospital with a child after an emergency to pick up essentials they may need for their child or themselves such as apparel and footwear, toiletries and more, free of charge. The Sugar Plum Shop provides an average of 260 patient families with gifts to help ease the burden of being in the hospital during the holiday season annually, while Children's Hospital Intervention and Prevention Services (CHIPS Center) promotes hope and healing for those affected by child abuse and neglect. The specialty-trained staff at the CHIPS Center provides more than 2,850 counseling sessions for children and families in need each year. “We are grateful to our partners at PUMA for helping us support the great work of Children’s of Alabama and the Care Closet, Sugar Plum Shop & CHIPS Center, for the third year in a row,” said Sarah Sharp-Wangaard, VP Marketing, Hibbett. “No one facing a child’s illness or accident should have to worry about basic supplies in a time of need and thanks to the staff and social workers at Children’s, they won’t have to.” “This partnership with Hibbett and Puma has provided valuable funding and resources for the Social Services team to be able to connect with patients and patient families when they are at their most vulnerable,” said Emily Hornak, Cause Marketing and Corporate Partnerships director, Children’s of Alabama. “The Care Closet allows for patients and patient families to receive clothes, shoes and other necessary items when they may have had to come to Children’s of Alabama urgently and unexpectedly. We are grateful to Hibbett and PUMA for their ongoing partnership with our mission.” The donation of 3,363 items was presented to Children’s of Alabama by Hibbett and PUMA on Tuesday, December 13, 2022. The shipment contained approximately 375 pairs of footwear, 1,988 items of clothing and 1,000 Poppit toys. About Hibbett, Inc. Headquartered in Birmingham, Alabama, Hibbett is a leading athletic-inspired fashion retailer with 1,126 Hibbett and City Gear specialty stores located in 36 states nationwide as of October 29, 2022. Hibbett has a rich history of convenient locations, personalized customer service, and access to coveted footwear, apparel and equipment from top brands like Nike, Jordan, and adidas. Consumers can browse styles, find new releases, shop looks, and make purchases online or in their nearest store by visiting www.hibbett.com. Follow us @hibbettsports and @citygear on Facebook, Instagram and Twitter. About Children’s of Alabama Since 1911, Children’s of Alabama has provided specialized medical care for ill and injured children, offering inpatient and outpatient services throughout central Alabama. Ranked among the best pediatric medical centers in the nation by U.S. News & World Report, Children’s provided care for youngsters from every county in Alabama and 42 other states last year, representing more than 684,000 outpatient visits and more than 15,000 inpatient admissions. With more than 3.5 million square feet, Children’s is one of the largest pediatric medical facilities in the United States. More information is available at childrensal.org. About PUMA PUMA is one of the world’s leading Sports Brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs more than 16,000 people worldwide, and is headquartered in Herzogenaurach/Germany. https://about.puma.com/ Contact Details Wendy Yellin pr@hibbett.com Company Website https://www.Hibbett.com

December 16, 2022 10:05 AM Eastern Standard Time

Image

Portugal National Funder FCT Agrees Transformative Agreement with Elsevier

Elsevier

Elsevier, a global leader in research publishing and information analytics has entered into a transformative agreement with b-on to enable continued reading access for researchers affiliated with b-on institutions and open access publishing. This is the first time Elsevier has signed a transformative agreement to support Portugal. It will benefit the member institutions with access to Elsevier's extensive collection of journals on ScienceDirect. The cost of publishing open access is covered under the terms of this agreement up to a pre-set annual cap. When publishing open access in hybrid journals, eligible corresponding authors do not have to pay an article publishing charge (APC). The new three-year contract will run until 31 st October 2024. Joana Novais, Manager of the b-on Consortium said: “This agreement lays an important stepping stone in the direction of Open Access in Portugal. It is a great honour for b-on to be able to contribute to this transition to OA by providing the authors of its member institutions the possibility to publish an annual average of 2000 OA articles in hybrid journals without incremental costs.” The b-on Consortium was founded in 2004 and represents 64 institutions, mainly higher education and research institutions across Portugal. It is managed by FCCN, a unit of FCT – Foundation for Science and Technology. William Rubens, Vice President, Elsevier said: "We are delighted to be working with the b-on Consortium to support their open access ambitions. We are thrilled to have agreed to our first Open Access agreement with them to ensure access to high-quality research and enable Portuguese researchers to publish with Elsevier, enabling them to share their findings globally." Elsevier aims to find the right solutions to meet the diverse needs of academic institutions, students, researchers, and funders worldwide while ensuring published research remains trusted and of high quality. Our approach with all customers is to understand their objectives and work with them to achieve these in an economically sustainable way while preserving the quality, integrity, and sustainability of the peer-review publishing system. For more on how Elsevier supports open access, please visit our website. About b-on B-on provides unlimited and permanent access to the full texts of thousands of scientific journals and online ebooks from some of the most important content providers, through subscriptions negotiated at national level. It started operating in March 2004 and is today a reference in access to international scientific information. It brings together higher education institutions, R&D institutions, hospitals, public institutions and private non-profit institutions. B-on currently reaches around 380.000 individuals affiliated with its 64 member institutions. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, LCUA, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Communications, UK Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Company Website https://www.elsevier.com/

December 16, 2022 08:20 AM Eastern Standard Time

Ellie Diagnostics Appoints Pat McCarthy as Chief Commercial Officer

Ellie Diagnostics

Ellie Diagnostics, the leading independent diagnostics services provider for veterinarians, today announced that Pat McCarthy has been named Chief Commercial Officer. In this new role, Mr. McCarthy will drive commercial operations and strategic initiatives across the entire organization. He has more than 25 years of experience leading commercial teams and corporate accounts business strategy with high-profile companies such as PSIvet, Pet Partners LLC and IDEXX Laboratories. “On behalf of our medical board, investors, and the entire Ellie team, we are pleased to welcome Pat to our group,” said Founder and Chief Executive Officer Mark DeCourcy. “He brings a wealth of animal health, and commercial experience to Ellie Diagnostics that will be extremely valuable as the company continues to grow, and strengthen its commercial strategy.” “I am very excited to join the Ellie Diagnostics team as CCO,” said Chief Commercial Officer Pat McCarthy. “The growth potential is astonishing, and the value of service Ellie provides veterinarians is tremendous, given its advanced laboratory technology and passionate people. I look forward to strengthening our commercial strategy, and execution for the tremendous growth that is forecasted for 2023 and beyond.” About Ellie Diagnostics Ellie Diagnostics is the fastest growing independent veterinary diagnostics company in the United States, providing innovative services to veterinarians nationwide. Ellie provides next-day lab results, complimentary shipping, pathology consultations, data protection, mobile access to orders and results and innovative laboratory reporting. Their comprehensive test menu includes routine lab testing, histopathology, cytology, microbiology, and a wide variety of specialty tests. To learn more, visit www.elliediagnostics.com. Contact Details Ellie Diagnostics Jeff Gwynn, Vice President of Marketing +1 972-619-9969 jgwynn@elliediagnostics.com

December 15, 2022 12:00 PM Eastern Standard Time